glp-1 kidney outcomes news today GLP therapies have established themselves as kidney-protective in type 2 diabetes and high risk of disease. This new post-hoc analysis of SURPASS-CVOT's kidney shows greater kidney protection with tirzepatide (#mounjaro) Kidney Outcomes With Glucagon-Like Peptide-1

However, it is crucial to recognise that medication is not a substitute for lifestyle interventions but rather an adjunct to support metabolic health

Protein should be prioritized at every meal

Indigestion symptoms typically improve as your body adjusts to the medication, usually within 4-8 weeks

Geopolitical and regulatory shocks are the base case going forward, said Dan Sanford, Vice President, Energy Practice Leader Executive and Professional Lines at Berkshire Hathaway Specialty Insurance (BHSI)

Bydureon)] was synthesized by encapsulating exenatide into microspheres of medical-grade poly-( D , L -lactide-co-glycolide) which enables the drug to be released over an extended period of time (DeYoung et al., 2011)

Ultramicroscopy 53 , 251270 (1994) Kucukelbir, A., Sigworth, F